Biomedical Approaches to HIV Prevention in Women
- 210 Downloads
Purpose of Review
Effective HIV prevention techniques for women are of critical importance, as nearly half of all HIV infections globally are in women. This article reviews the recent literature on biomedical approaches to HIV prevention in women.
In trials in which women were adherent to oral pre-exposure prophylaxis (PrEP), PrEP was equally efficacious in men and women. However, in studies of oral PrEP exclusively in women, adherence was low, and it was not efficacious. In trials of topical PrEP, including vaginal tenofovir gel and the monthly dapivirine ring, efficacy was also dependent upon adherence. Treatment as prevention (TasP) is a very effective HIV prevention strategy, though limited in that it is not controlled by the HIV-uninfected partner.
Adherence is an important factor in the efficacy of biomedical interventions for HIV prevention in women; continued research is needed to identify the most efficacious and acceptable agents for women. Oral PrEP is currently recommended for the following groups of HIV-negative women: heterosexual women in ongoing sexual relationships with a partner infected with or at substantial risk of HIV infection and women who inject drugs and share injection or drug preparation equipment.
KeywordsWomen HIV prevention Pre-exposure prophylaxis (PrEP) Post-exposure prophylaxis (PEP) Treatment as prevention (TasP)
Compliance with Ethical Standards
Conflict of Interest
Christine Heumann declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.UNAIDS DATA 2017. http://aidsdatahub.org/unaids-data-2017-unaids-2017-0.
- 2.Women|Gender|HIV by Group|HIV/AIDS| CDC. 2017. https://www.cdc.gov/hiv/group/gender/women/index.html.
- 3.Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes R, et al. Heterosexual risk of HIV-1 infection per sexual act: a systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118–29. https://doi.org/10.1016/S1473-3099(09)70021-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Intersection of Intimate Partner Violence and HIV in Women | National Prevention Information Network. Centers for Disease Control and Prevention, National Center for HIV Viral Hepatitis STD and TB Prevention. 2014. https://npin.cdc.gov/publication/intersection-intimate-partner-violence-and-hiv-women.
- 8.Economically Disadvantaged|HIV by Group|HIV/AIDS|CDC. 2017. https://www.cdc.gov/hiv/group/poverty.html.
- 10.Injection Drug Use|HIV Risk and Prevention|HIV/AIDS|CDC. 2017. https://www.cdc.gov/hiv/risk/idu.html.
- 11.Crime UNOoDa. HIV/AIDS Prevention and Care for Female Injection Drug Users. 2006. http://www.unodc.org/pdf/HIV-AIDS_femaleIDUs_Aug06.pdf.
- 12.Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. The Cochrane database of systematic reviews. 2002(1):Cd003255. doi: https://doi.org/10.1002/14651858.cd003255.
- 14.Act Against AIDS | Basics|HIV Prevention|Can using lubricant help reduce my HIV risk?|Center for Disease Control and Prevention. 2018. https://www.cdc.gov/actagainstaids/basics/prevention.html.
- 15.Kennedy CE, Bernard LJ, Muessig KE, Konda KA, Akl EA, Lo YR, et al. Serosorting and HIV/STI infection among HIV-negative MSM and transgender people: a systematic review and meta-analysis to inform WHO guidelines. J Sex Transm Dis. 2013;2013:583627. https://doi.org/10.1155/2013/583627.PubMedPubMedCentralGoogle Scholar
- 16.Effective HIV Prevention Strategies| HIV Risk and Prevention Estimates|HIV Risk and Prevention|HIV/AIDS| CDC. 2017. https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html.
- 17.Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92. https://doi.org/10.1007/s10461-013-0593-y.CrossRefPubMedGoogle Scholar
- 18.CDC. HIV and injection drug use—vital signs. @CDCgov. 2016. https://www.cdc.gov/vitalsigns/hiv-drug-use/index.html.
- 19.Sciences G. Truvada Access (Gilead Sciences, Inc): FDA Package Insert. 2016. http://medlibrary.org/lib/rx/meds/truvada-access-1/.
- 21.Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (London, England). 2013;27(13):2155–60. https://doi.org/10.1097/QAD.0b013e3283629037. CrossRefGoogle Scholar
- 24.• Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. https://doi.org/10.1056/NEJMoa1202614. In this study of oral PrEP in heterosexual women (FEM-PrEP), participants were randomized to TDF or placebo. Unfortunately, there was no reduction in HIV acquistion, and the study was stopped early because of a lack of efficacy. It was speculated that adherence was a major factor in these result. CrossRefPubMedPubMedCentralGoogle Scholar
- 25.•• Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18. https://doi.org/10.1056/NEJMoa1402269. In this study of PrEP in heterosexual women (VOICE), participants were randomized to TDF, TDF-FTC, 1% tenfovir gel, or placebo. There was no significant reduction in the HIV infection rate with any of the interventions. Adherence was a major issue in this study. CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2013;381(9883):2083–90. https://doi.org/10.1016/s0140-6736(13)61127-7.CrossRefGoogle Scholar
- 27.Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (London, England). 2006;20(4):543–51. https://doi.org/10.1097/01.aids.0000210608.70762.c3. CrossRefGoogle Scholar
- 28.Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (New York, NY). 2010;329(5996):1168–74. https://doi.org/10.1126/science.1193748.CrossRefGoogle Scholar
- 29.Rees HD-M, Sinead A, Lombard C, Baron D, Panchia R, Myer L, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Seattle: CROI; 2015.Google Scholar
- 32.Announcement. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV—United States, 2016. MMWR Morbidity and mortality weekly report. 2016;65(17):458. doi: https://doi.org/10.15585/mmwr.mm6517a5.
- 33.Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337(21):1485–90. https://doi.org/10.1056/nejm199711203372101. CrossRefPubMedGoogle Scholar
- 35.Linden JA, Oldeg P, Mehta SD, McCabe KK, LaBelle C. HIV postexposure prophylaxis in sexual assault: current practice and patient adherence to treatment recommendations in a large urban teaching hospital. Acad Emerg Med. 2005;12(7):640–6. https://doi.org/10.1197/j.aem.2005.01.015.CrossRefPubMedGoogle Scholar
- 37.• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. https://doi.org/10.1056/NEJMoa1105243. In this study (HPTN052), treatment as prevention was found to be an extremely effective HIV prevention strategy. Couples were randomized to either early or delayed initiation of antiretroviral therapy, and HIV transmission was decreased by 96% in the early initiation group. CrossRefPubMedPubMedCentralGoogle Scholar
- 38.van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118. https://doi.org/10.1371/journal.pone.0089118.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55–64. https://doi.org/10.1093/infdis/jiw077. CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8(1):e55013. https://doi.org/10.1371/journal.pone.0055013.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Heffron R, McClelland RS, Balkus JE, Celum C, Cohen CR, Mugo N, et al. Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV. 2017;4(10):e449–e56. https://doi.org/10.1016/s2352-3018(17)30110-8. CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96(3):314–23. https://doi.org/10.1038/clpt.2014.118.CrossRefPubMedGoogle Scholar
- 44.Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e40. https://doi.org/10.1016/s2352-3018(17)30068-1. CrossRefPubMedGoogle Scholar
- 45.Woodsong C, Musara P, Chandipwisa A, Montgomery E, Alleman P, Chirenje M, et al. Interest in multipurpose prevention of HIV and pregnancy: perspectives of women, men, health professionals and community stakeholders in two vaginal gel studies in southern Africa. BJOG. 2014;121(Suppl 5):45–52. https://doi.org/10.1111/1471-0528.12875. CrossRefPubMedGoogle Scholar
- 46.US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014. A clinical practice guideline. https://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf.